Javascript must be enabled to continue!
Global estimation of the bleeding episodes treatable with desmopressin in von Willebrand disease and hemophilia A
View through CrossRef
Desmopressin increases plasma factor VIII and von Willebrand factor in non-severe hemophilia A (Hem A) and type 1 von Willebrand disease (VWD), following intravenous infusions, subcutaneous injections, or nasal spray. This medication, with almost 50 years of clinical experience and proven safety and efficacy, is often unavailable. Thus, there is a need to establish how many patients can benefit from it and how many bleeding episodes can be treated. We reviewed the literature to estimate the global prevalence of symptomatic patients with VWD type 1 and non-severe Hem A, the incidence of bleeds, and the rate of responsiveness to desmopressin. Real-world data indicate that 1.7 patients with VWD per 100,000 seek care in specialized centers. Of them, 1.15 per 100,000 have type 1 VWD and 80% are reported to respond to desmopressin. In type 1 VWD, the estimated frequency of bleeds treatable with desmopressin are 2.5 events per patient year. Non-severe cases are 45% of all Hem A cases, with a much lower incidence of bleeds than in severe disease (0.4 events / patient / year). Based on epidemiology, data on the rates of bleeding, and desmopressin responsiveness, we estimated that 84,000 people with VWD type 1 would benefit from desmopressin to treat 210,000 yearly bleeds, and that 81,000 people with non-severe Hem A can be treated yearly for 13,000 bleeds. Desmopressin is an essential therapeutic tool in non-severe Hem A and type 1 VWD that can treat more than 220,000 bleeding episodes successfully, safely, and economically, also in low-income settings with poor access to costly replacement therapies.
Ferrata Storti Foundation (Haematologica)
Title: Global estimation of the bleeding episodes treatable with desmopressin in von Willebrand disease and hemophilia A
Description:
Desmopressin increases plasma factor VIII and von Willebrand factor in non-severe hemophilia A (Hem A) and type 1 von Willebrand disease (VWD), following intravenous infusions, subcutaneous injections, or nasal spray.
This medication, with almost 50 years of clinical experience and proven safety and efficacy, is often unavailable.
Thus, there is a need to establish how many patients can benefit from it and how many bleeding episodes can be treated.
We reviewed the literature to estimate the global prevalence of symptomatic patients with VWD type 1 and non-severe Hem A, the incidence of bleeds, and the rate of responsiveness to desmopressin.
Real-world data indicate that 1.
7 patients with VWD per 100,000 seek care in specialized centers.
Of them, 1.
15 per 100,000 have type 1 VWD and 80% are reported to respond to desmopressin.
In type 1 VWD, the estimated frequency of bleeds treatable with desmopressin are 2.
5 events per patient year.
Non-severe cases are 45% of all Hem A cases, with a much lower incidence of bleeds than in severe disease (0.
4 events / patient / year).
Based on epidemiology, data on the rates of bleeding, and desmopressin responsiveness, we estimated that 84,000 people with VWD type 1 would benefit from desmopressin to treat 210,000 yearly bleeds, and that 81,000 people with non-severe Hem A can be treated yearly for 13,000 bleeds.
Desmopressin is an essential therapeutic tool in non-severe Hem A and type 1 VWD that can treat more than 220,000 bleeding episodes successfully, safely, and economically, also in low-income settings with poor access to costly replacement therapies.
Related Results
Desmopressin stimulation testing: Response to intravenous and intranasal forms
Desmopressin stimulation testing: Response to intravenous and intranasal forms
IntroductionDesmopressin is commonly used to reduce bleeding in patients with mucocutaneous bleeding disorders and is available in both intravenous and intranasal forms. Given the ...
Hemophilia prevalence in Azerbaijan
Hemophilia prevalence in Azerbaijan
Aim. Assessment of hemophilia prevalence in Azerbaijan.Methods. Materials of the study were the data of the registry on hemophilia. Prevalence and its structure were calculated for...
An Antibody to Tissue Factor Pathway Inhibitor (PF-06741086) in Combination with Recombinant Factor VIIa Increases Hemostasis in Hemophilia Plasma without Excessive Thrombin Generation
An Antibody to Tissue Factor Pathway Inhibitor (PF-06741086) in Combination with Recombinant Factor VIIa Increases Hemostasis in Hemophilia Plasma without Excessive Thrombin Generation
Abstract
Hemophilia is a hereditary bleeding disorder caused by intrinsic coagulation pathway deficiencies of Factor VIII (hemophilia A) or Factor IX (hemophilia B)....
Pedersstræde i Viborg. Købstadarkæologiske undersøgelser 1966/67
Pedersstræde i Viborg. Købstadarkæologiske undersøgelser 1966/67
Pedersstræde in Viborg Archäologische Untersuchungen der Stadt ViborgSchon seit dem 17. Jahrhundert hat man die historisch-topographische Entwicklung der Stadt Viborg zum Gegenstan...
Management of Bleeding In Acquired Hemophilia: Results of the European Acquired Hemophilia Registry (EACH2)
Management of Bleeding In Acquired Hemophilia: Results of the European Acquired Hemophilia Registry (EACH2)
Abstract
Abstract 716
Objective.
Acquired hemophilia (AH) is a hemorrhagic syndrome, caused by autoantibodies inh...
Effects of desmopressin on thrombogenesis in aspirin‐induced platelet dysfunction
Effects of desmopressin on thrombogenesis in aspirin‐induced platelet dysfunction
Summary. Aspirin causes a coagulation disorder. Desmopressin has haemostatic effects by increasing the plasma levels of coagulation factor VIII and von Willebrand factor. The preci...
Hemophilia
Hemophilia
Hemophilia is a family of rare bleeding disorders characterized by deficiency of clotting factors. Hemophilia A is an inherited deficiency of factor VIII, whereas hemophilia B (Chris...
The Prevalence of Cardiovascular Risk Factors in Individuals with Hemophilia
The Prevalence of Cardiovascular Risk Factors in Individuals with Hemophilia
Abstract
Abstract 4319
Background:
Increasing life expectancy in individuals with hemophilia has lead to a higher...

